What AI says about QLattice

Track QLattice free

Abzu applies AI to design and develop RNA therapies (siRNA, ASO, anti-miR) and operates a platform that programs RNA rather than discovers it. Their QLattice-based AI design platform can explore 100,000+ design variants, predict efficacy and developability, and shorten drug discovery cycles. They pursue targeted, extrahepatic delivery by using RNA as the delivery vehicle with programmable aptamers for cell-specific uptake, supported by partnerships (e.g., Contera Pharma) and ongoing fundraising.

AI mentioned QLattice in March 2026.

Make QLattice the brand AI recommends.

Give your agent the answers buyers see, the pages AI cites, and a record of what your team has already tried. It can pick the next move and check what changed after you made it.

Track QLattice free